184 related articles for article (PubMed ID: 8747372)
1. Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Szabo E; Mao JT; Lam S; Reid ME; Keith RL
Chest; 2013 May; 143(5 Suppl):e40S-e60S. PubMed ID: 23649449
[TBL] [Abstract][Full Text] [Related]
2. Suppression of tumour development by substances derived from the diet--mechanisms and clinical implications.
Gescher A; Pastorino U; Plummer SM; Manson MM
Br J Clin Pharmacol; 1998 Jan; 45(1):1-12. PubMed ID: 9489587
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of neuroblastoma: progress and promise beyond uncertainties.
Aravindan N; Natarajan M; Somasundaram DB; Aravindan S
J Cancer Metastasis Treat; 2023; 9():. PubMed ID: 38249515
[TBL] [Abstract][Full Text] [Related]
4. Endogenous estrogen metabolites as oxidative stress mediators and endometrial cancer biomarkers.
Bukato K; Kostrzewa T; Gammazza AM; Gorska-Ponikowska M; Sawicki S
Cell Commun Signal; 2024 Apr; 22(1):205. PubMed ID: 38566107
[TBL] [Abstract][Full Text] [Related]
5. Considerations for using potential surrogate endpoints in cancer screening trials.
Webb AB; Berg CD; Castle PE; Crosby D; Etzioni R; Kessler LG; Menon U; Parmar M; Steele RJC; Sasieni PD
Lancet Oncol; 2024 May; 25(5):e183-e192. PubMed ID: 38697164
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of lung cancer: prospects and disappointments in human clinical trials.
Greenberg AK; Tsay JC; Tchou-Wong KM; Jorgensen A; Rom WN
Cancers (Basel); 2013 Jan; 5(1):131-48. PubMed ID: 24216701
[TBL] [Abstract][Full Text] [Related]
7. Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age.
Cummings SR; Kritchevsky SB
Geroscience; 2022 Dec; 44(6):2925-2931. PubMed ID: 36260264
[TBL] [Abstract][Full Text] [Related]
8. Phytochemicals in Cancer Treatment and Cancer Prevention-Review on Epidemiological Data and Clinical Trials.
Rudzińska A; Juchaniuk P; Oberda J; Wiśniewska J; Wojdan W; Szklener K; Mańdziuk S
Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111115
[TBL] [Abstract][Full Text] [Related]
9. Retinoids for preventing the progression of cervical intra-epithelial neoplasia.
Helm CW; Lorenz DJ; Meyer NJ; Rising WW; Wulff JL
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD003296. PubMed ID: 23740788
[TBL] [Abstract][Full Text] [Related]
10. A Mediterranean dietary intervention in persons at high risk of colon cancer: recruitment and retention to an intensive study requiring biopsies.
Djuric Z; Ruffin MT; Rapai ME; Cornellier ML; Ren J; Ferreri TG; Askew LM; Sen A; Brenner DE; Turgeon DK
Contemp Clin Trials; 2012 Sep; 33(5):881-8. PubMed ID: 22640923
[TBL] [Abstract][Full Text] [Related]
11. Protein kinases controlling PCNA and p53 expression in human ovarian cells.
Sirotkin AV; Ovcharenko D; Benco A; Mlyncek M
Funct Integr Genomics; 2009 May; 9(2):185-95. PubMed ID: 19067003
[TBL] [Abstract][Full Text] [Related]
12. Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies.
de Jong MD; Boucher CA; Cooper DA; Galasso GJ; Gazzard B; Lange JM; Montaner JS; Richman DD; Thomas HC
Antiviral Res; 1997 Jul; 35(2):65-82. PubMed ID: 9217244
[No Abstract] [Full Text] [Related]
13. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
14. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of prostate cancer: concepts and strategies.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovitch L; Malone WA; Crowell JA; Sigman CC
Eur Urol; 1999; 35(5-6):342-50. PubMed ID: 10325487
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
18. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
